Halozyme Therapeutics (HALO) PT Raised to $26 at BMO Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Halozyme Therapeutics (HALO) Raised to $19 at Piper Jaffray
March 3, 2015 7:17 AM ESTPiper Jaffray analyst Charles Duncan reiterated an Overweight rating and boosted his price target on Halozyme Therapeutics (NASDAQ: HALO) to $19.00 (from $17.00) following Q4 results.. The firm said proprietary program visibility should increase in 2015.
Duncan commented, "On Monday AMC, Halozyme reported 4Q/FY14 results, reiterating 2015... More
Halozyme Therapeutics (HALO) Tops Q4 EPS by 3c; Guides FY15 Revs
March 2, 2015 4:17 PM ESTHalozyme Therapeutics (NASDAQ: HALO) reported Q4 EPS of ($0.04), $0.03 better than the analyst estimate of ($0.07). Revenue for the quarter came in at $30.38 million versus the consensus estimate of $25.6 million.
Halozyme Therapeutics sees FY2015 EPS of $85.00-$95.00, versus the consensus of $97.70.
For earnings history and... More
